Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New cancer drug hope

27.10.2006
Scientists helping to develop the next generation of cancer-beating drugs say they have had a major breakthrough with their latest results.

A new class of drugs – being developed by a major pharmaceutical company – targets an enzyme that helps cells divide; in cancer, this enzyme, called Aurora B, goes into overdrive, possibly leading to uncontrolled and abnormal cell divisions.

The University of Manchester team has been studying a chemical that blocks, or inhibits, the catalytic actions of Aurora B and has proven very effective at killing cancer cells in cultures grown in the laboratory.

“The first compounds were designed to inhibit a related enzyme called Aurora A,” said Dr Stephen Taylor, who is leading the research in Manchester’s Faculty of Life Sciences.

... more about:
»Cancer »Inhibitor »enzyme »inhibit

“But our research has shown that inhibiting Aurora B is a far more successful method of killing cancer cells and we have been strongly encouraged by these latest results.”

The research – published in the Journal of Cell Science – will be of interest to scientists around the world looking at Aurora inhibitors; there are currently more than 10 companies pursuing Aurora cancer programmes.

“Auroras have attracted worldwide attention but no one has been entirely sure which strategy to follow,” said Dr Taylor.

“Our paper clearly demonstrates that targeting Aurora B is a highly attractive avenue to pursue, although inhibition of Aurora A may still have some merits as a potential therapy.”

Early clinical trials of the Aurora-B drug’s toxicity have also been encouraging, with no major adverse effects to patients being reported. The next stage of trials to test its effectiveness is likely to start shortly.

“A lot of current cancer drugs, while effective, are also toxic; by contrast, the toxic effects of Aurora inhibitors has been relatively mild and so could provide a revolutionary new way to treat cancer in the future.”

Aurora A and B are a type of enzyme known as protein kinases; they modify other proteins by chemically adding phosphate groups to them. In cancer, both these protein kinases are ‘overexpressed’.

The University of Manchester team has been working on the Aurora B inhibitor in collaboration with pharmaceutical company AstraZeneca. The group published an earlier paper in 2003 that highlighted the potential success of targeting Aurora B. These latest findings further strengthen the team’s belief that Aurora B inhibition is the preferred route to an effective cancer therapy.

Aeron Haworth | alfa
Further information:
http://www.manchester.ac.uk

Further reports about: Cancer Inhibitor enzyme inhibit

More articles from Life Sciences:

nachricht A Map of the Cell’s Power Station
18.08.2017 | Albert-Ludwigs-Universität Freiburg im Breisgau

nachricht On the way to developing a new active ingredient against chronic infections
18.08.2017 | Deutsches Zentrum für Infektionsforschung

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Fizzy soda water could be key to clean manufacture of flat wonder material: Graphene

Whether you call it effervescent, fizzy, or sparkling, carbonated water is making a comeback as a beverage. Aside from quenching thirst, researchers at the University of Illinois at Urbana-Champaign have discovered a new use for these "bubbly" concoctions that will have major impact on the manufacturer of the world's thinnest, flattest, and one most useful materials -- graphene.

As graphene's popularity grows as an advanced "wonder" material, the speed and quality at which it can be manufactured will be paramount. With that in mind,...

Im Focus: Exotic quantum states made from light: Physicists create optical “wells” for a super-photon

Physicists at the University of Bonn have managed to create optical hollows and more complex patterns into which the light of a Bose-Einstein condensate flows. The creation of such highly low-loss structures for light is a prerequisite for complex light circuits, such as for quantum information processing for a new generation of computers. The researchers are now presenting their results in the journal Nature Photonics.

Light particles (photons) occur as tiny, indivisible portions. Many thousands of these light portions can be merged to form a single super-photon if they are...

Im Focus: Circular RNA linked to brain function

For the first time, scientists have shown that circular RNA is linked to brain function. When a RNA molecule called Cdr1as was deleted from the genome of mice, the animals had problems filtering out unnecessary information – like patients suffering from neuropsychiatric disorders.

While hundreds of circular RNAs (circRNAs) are abundant in mammalian brains, one big question has remained unanswered: What are they actually good for? In the...

Im Focus: RAVAN CubeSat measures Earth's outgoing energy

An experimental small satellite has successfully collected and delivered data on a key measurement for predicting changes in Earth's climate.

The Radiometer Assessment using Vertically Aligned Nanotubes (RAVAN) CubeSat was launched into low-Earth orbit on Nov. 11, 2016, in order to test new...

Im Focus: Scientists shine new light on the “other high temperature superconductor”

A study led by scientists of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science in Hamburg presents evidence of the coexistence of superconductivity and “charge-density-waves” in compounds of the poorly-studied family of bismuthates. This observation opens up new perspectives for a deeper understanding of the phenomenon of high-temperature superconductivity, a topic which is at the core of condensed matter research since more than 30 years. The paper by Nicoletti et al has been published in the PNAS.

Since the beginning of the 20th century, superconductivity had been observed in some metals at temperatures only a few degrees above the absolute zero (minus...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Call for Papers – ICNFT 2018, 5th International Conference on New Forming Technology

16.08.2017 | Event News

Sustainability is the business model of tomorrow

04.08.2017 | Event News

Clash of Realities 2017: Registration now open. International Conference at TH Köln

26.07.2017 | Event News

 
Latest News

A Map of the Cell’s Power Station

18.08.2017 | Life Sciences

Engineering team images tiny quasicrystals as they form

18.08.2017 | Physics and Astronomy

Researchers printed graphene-like materials with inkjet

18.08.2017 | Materials Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>